Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127530991 | 12753099 | 1 | I | 20160823 | 20160916 | 20160916 | EXP | US-ROCHE-1829339 | ROCHE | 56.00 | YR | M | Y | 79.00000 | KG | 20160916 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127530991 | 12753099 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | OVER 30-90 MINUTES ON DAYS 1 AND 15?LAST TREATMENT RECEIVED ON 10/MAR/2010 | U | 125085 | 1700 | MG | |||||||
| 127530991 | 12753099 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1700 | MG | ||||||||
| 127530991 | 12753099 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1700 | MG | ||||||||
| 127530991 | 12753099 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 850 | MG | ||||||||
| 127530991 | 12753099 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1700 | MG | ||||||||
| 127530991 | 12753099 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | ON DAYS 1, 8, 15, AND 22?LAST TREATMENT RECEIVED ON 10/MAR/2010 | U | 0 | 75 | MG | |||||||
| 127530991 | 12753099 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 60 | MG | ||||||||
| 127530991 | 12753099 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 60 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127530991 | 12753099 | 1 | Pancreatic neoplasm |
| 127530991 | 12753099 | 6 | Pancreatic neoplasm |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127530991 | 12753099 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127530991 | 12753099 | Hypertension | |
| 127530991 | 12753099 | Lymphocyte count decreased | |
| 127530991 | 12753099 | Pulmonary haemorrhage | |
| 127530991 | 12753099 | Stomatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127530991 | 12753099 | 1 | 20091028 | 0 | ||
| 127530991 | 12753099 | 2 | 20091125 | 0 | ||
| 127530991 | 12753099 | 3 | 20091230 | 0 | ||
| 127530991 | 12753099 | 4 | 20100210 | 0 | ||
| 127530991 | 12753099 | 5 | 20100224 | 0 | ||
| 127530991 | 12753099 | 6 | 20091028 | 0 | ||
| 127530991 | 12753099 | 7 | 20091125 | 0 | ||
| 127530991 | 12753099 | 8 | 20091230 | 0 |